Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Spark Therapeutics Inc's Business Segments
Spark Therapeutics Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
-
Largest Segment
-
Total Revenue
$ 22
Regions Reported
-
Spark Therapeutics Inc does not report a distinct business-segment axis in its filings - its disaggregated revenue is disclosed by product and service category instead. See the Product & Service breakdown below.
Revenue by Product & Service Category - FY
- Contract Revenue69.2%
- Product30.8%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Contract Revenue | $ 16 | 69.2% |
| Product | $ 7 | 30.8% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Description of Spark Therapeutics Inc
Spark Therapeutics Inc. is a leading gene therapy company dedicated to discovering, developing, and delivering curative gene therapies for a wide range of genetic diseases. The company was founded in 2013 and is headquartered in Philadelphia, Pennsylvania.
Spark Therapeutics focuses on developing innovative treatments using adeno-associated viral (AAV) vectors as delivery vehicles to transport corrective genes into specific cells of the body. This approach aims to address the root cause of genetic diseases by providing functional copies of the defective genes and potentially restoring normal cellular function.
The company's pipeline consists of numerous gene therapy candidates targeting different genetic disorders. One of their most notable advancements has been the development of Luxturna (voretigene neparvovec), the first gene therapy approved in the United States for a genetic disease. Luxturna provides a one-time treatment option for patients with inherited retinal diseases caused by specific mutations, allowing them to regain some degree of vision.
Spark Therapeutics has a robust research and development team, employing cutting-edge technologies to identify and target genes associated with various diseases. They collaborate with leading academic institutions, research organizations, and other biotechnology companies to accelerate gene therapy development and improve treatment options for patients.
In addition to their development programs, Spark Therapeutics is committed to ensuring access to their gene therapies. They work closely with payers, policymakers, and patient advocacy groups to establish reimbursement programs and explore innovative payment models that address the unique challenges of gene therapy treatments.
The company has also established manufacturing capabilities to support the commercialization of their gene therapies. They operate a state-of-the-art facility in Philadelphia, which is capable of producing AAV vectors at large scales while adhering to stringent quality control standards.
Spark Therapeutics has received recognition for its groundbreaking research and development efforts. Their pioneering work in gene therapy has garnered support from renowned institutions, including the National Institutes of Health (NIH) and the U.S. Department of Defense, further fueling their pursuit of novel treatments for genetic diseases.
Overall, Spark Therapeutics Inc. strives to transform the lives of patients by harnessing the potential of gene therapy to provide long-term and potentially curative treatments for genetic diseases. Through their innovative research, strategic partnerships, and commitment to accessibility, the company stands at the forefront of the rapidly evolving field of gene therapy.
Spark Therapeutics focuses on developing innovative treatments using adeno-associated viral (AAV) vectors as delivery vehicles to transport corrective genes into specific cells of the body. This approach aims to address the root cause of genetic diseases by providing functional copies of the defective genes and potentially restoring normal cellular function.
The company's pipeline consists of numerous gene therapy candidates targeting different genetic disorders. One of their most notable advancements has been the development of Luxturna (voretigene neparvovec), the first gene therapy approved in the United States for a genetic disease. Luxturna provides a one-time treatment option for patients with inherited retinal diseases caused by specific mutations, allowing them to regain some degree of vision.
Spark Therapeutics has a robust research and development team, employing cutting-edge technologies to identify and target genes associated with various diseases. They collaborate with leading academic institutions, research organizations, and other biotechnology companies to accelerate gene therapy development and improve treatment options for patients.
In addition to their development programs, Spark Therapeutics is committed to ensuring access to their gene therapies. They work closely with payers, policymakers, and patient advocacy groups to establish reimbursement programs and explore innovative payment models that address the unique challenges of gene therapy treatments.
The company has also established manufacturing capabilities to support the commercialization of their gene therapies. They operate a state-of-the-art facility in Philadelphia, which is capable of producing AAV vectors at large scales while adhering to stringent quality control standards.
Spark Therapeutics has received recognition for its groundbreaking research and development efforts. Their pioneering work in gene therapy has garnered support from renowned institutions, including the National Institutes of Health (NIH) and the U.S. Department of Defense, further fueling their pursuit of novel treatments for genetic diseases.
Overall, Spark Therapeutics Inc. strives to transform the lives of patients by harnessing the potential of gene therapy to provide long-term and potentially curative treatments for genetic diseases. Through their innovative research, strategic partnerships, and commitment to accessibility, the company stands at the forefront of the rapidly evolving field of gene therapy.
Spark Therapeutics Inc. a subsidiary of Roche Holding AG, is at the forefront of the biotechnology industry, specializing in gene therapy aimed at addressing genetic diseases. The company operates primarily within a single segment: the development and commercialization of innovative gene therapies.
Segments
1. Development and Commercialization of Gene Therapies: Spark Therapeutics is committed to developing cutting-edge gene therapies that target various genetic disorders. The company’s focus lies in utilizing gene-editing technologies and innovative delivery systems that aim to provide long-lasting solutions for patients suffering from inherited diseases. Since its inception, the company has been notably impactful in the realm of rare genetic disorders, with a keen interest in advancing research and solutions for diseases that lack effective treatment options.
Products
Spark Therapeutics has developed several groundbreaking gene therapies that address significant unmet medical needs. Among its portfolio, the following products are prominently featured:
1. LUXTURNA (voretigene neparvovec): As the first FDA-approved gene therapy for an inherited retinal disease, LUXTURNA offers a revolutionary treatment for patients with biallelic RPE65 mutation-associated retinal dystrophy. This groundbreaking therapy works by delivering a normal copy of the RPE65 gene directly to the retinal cells, thereby restoring the production of the protein needed for vision. Clinical studies have demonstrated its efficacy in improving functional vision, highlighting its significant impact on the quality of life for patients.
2. SPK-7001: Currently in clinical development, SPK-7001 is a gene therapy candidate targeting choroideremia, a rare genetic condition that leads to progressive vision loss. This therapeutic approach aims to deliver a functional copy of the CHM gene, which is essential for retinal health. The product represents ongoing efforts to address conditions where genetic defects directly lead to severe visual impairment.
3. SPK-8001: This project focuses on hemophilia A, a genetic disorder characterized by insufficient levels of clotting factor VIII. The gene therapy seeks to provide a stable and durable expression of the factor VIII protein to facilitate normal blood clotting, thus halting the bleeding episodes experienced by patients. Ongoing research seeks to demonstrate the long-term safety and efficacy of this therapy.
4. SPK-3006: This investigational gene therapy is designed to treat certain forms of Leukodystrophy caused by mutations in the ARSA gene. The approach aims to deliver a therapeutic gene that can help restore the function of the missing or malfunctioning enzyme, facilitating better neurological outcomes for affected individuals.
Services
Beyond its innovative gene therapy products, Spark Therapeutics offers a suite of services dedicated to enhancing the patient experience and improving accessibility to gene therapies. These services include:
1. Patient Support Programs: Spark Therapeutics is committed to ensuring that patients can effectively navigate the complexities of gene therapy. The Patient Support Programs offer personalized assistance tailored to individual patient needs. This support may encompass financial aid for treatment costs, guidance through insurance reimbursement processes, and connections to healthcare providers specializing in gene therapies. By providing comprehensive care, the company strives to alleviate the burdens faced by patients and their families during treatment.
2. Education and Awareness Initiatives: Recognizing the importance of education in advancing treatment options, Spark Therapeutics engages in numerous outreach efforts to enhance understanding of genetic disorders and existing therapies. These initiatives are aimed at patients, caregivers, and healthcare professionals, and involve collaboration with advocacy groups and participation in medical conferences. By raising awareness about gene therapy, the company seeks to foster informed discussions around treatment pathways and available resources.
3. Clinical Trials and Research: Spark Therapeutics places a strong emphasis on research to further the field of gene therapy. By conducting rigorous clinical trials, the company collects critical data that inform ongoing and future therapeutic developments. Through these trials, Spark aims to explore novel treatments for a broad spectrum of genetic diseases. The clinical research not only underpins the safety and efficacy of their gene therapies but also contributes to a greater understanding of genetic diseases at large.
In summary, Spark Therapeutics Inc. is a pioneering force in the biotechnology sector, dedicated to the development and commercialization of impactful gene therapies. Their flagship product, LUXTURNA, exemplifies their innovative approach to treatment, while their additional products and services demonstrate a holistic commitment to patient care, education, and research in genetic diseases.
Segments
1. Development and Commercialization of Gene Therapies: Spark Therapeutics is committed to developing cutting-edge gene therapies that target various genetic disorders. The company’s focus lies in utilizing gene-editing technologies and innovative delivery systems that aim to provide long-lasting solutions for patients suffering from inherited diseases. Since its inception, the company has been notably impactful in the realm of rare genetic disorders, with a keen interest in advancing research and solutions for diseases that lack effective treatment options.
Products
Spark Therapeutics has developed several groundbreaking gene therapies that address significant unmet medical needs. Among its portfolio, the following products are prominently featured:
1. LUXTURNA (voretigene neparvovec): As the first FDA-approved gene therapy for an inherited retinal disease, LUXTURNA offers a revolutionary treatment for patients with biallelic RPE65 mutation-associated retinal dystrophy. This groundbreaking therapy works by delivering a normal copy of the RPE65 gene directly to the retinal cells, thereby restoring the production of the protein needed for vision. Clinical studies have demonstrated its efficacy in improving functional vision, highlighting its significant impact on the quality of life for patients.
2. SPK-7001: Currently in clinical development, SPK-7001 is a gene therapy candidate targeting choroideremia, a rare genetic condition that leads to progressive vision loss. This therapeutic approach aims to deliver a functional copy of the CHM gene, which is essential for retinal health. The product represents ongoing efforts to address conditions where genetic defects directly lead to severe visual impairment.
3. SPK-8001: This project focuses on hemophilia A, a genetic disorder characterized by insufficient levels of clotting factor VIII. The gene therapy seeks to provide a stable and durable expression of the factor VIII protein to facilitate normal blood clotting, thus halting the bleeding episodes experienced by patients. Ongoing research seeks to demonstrate the long-term safety and efficacy of this therapy.
4. SPK-3006: This investigational gene therapy is designed to treat certain forms of Leukodystrophy caused by mutations in the ARSA gene. The approach aims to deliver a therapeutic gene that can help restore the function of the missing or malfunctioning enzyme, facilitating better neurological outcomes for affected individuals.
Services
Beyond its innovative gene therapy products, Spark Therapeutics offers a suite of services dedicated to enhancing the patient experience and improving accessibility to gene therapies. These services include:
1. Patient Support Programs: Spark Therapeutics is committed to ensuring that patients can effectively navigate the complexities of gene therapy. The Patient Support Programs offer personalized assistance tailored to individual patient needs. This support may encompass financial aid for treatment costs, guidance through insurance reimbursement processes, and connections to healthcare providers specializing in gene therapies. By providing comprehensive care, the company strives to alleviate the burdens faced by patients and their families during treatment.
2. Education and Awareness Initiatives: Recognizing the importance of education in advancing treatment options, Spark Therapeutics engages in numerous outreach efforts to enhance understanding of genetic disorders and existing therapies. These initiatives are aimed at patients, caregivers, and healthcare professionals, and involve collaboration with advocacy groups and participation in medical conferences. By raising awareness about gene therapy, the company seeks to foster informed discussions around treatment pathways and available resources.
3. Clinical Trials and Research: Spark Therapeutics places a strong emphasis on research to further the field of gene therapy. By conducting rigorous clinical trials, the company collects critical data that inform ongoing and future therapeutic developments. Through these trials, Spark aims to explore novel treatments for a broad spectrum of genetic diseases. The clinical research not only underpins the safety and efficacy of their gene therapies but also contributes to a greater understanding of genetic diseases at large.
In summary, Spark Therapeutics Inc. is a pioneering force in the biotechnology sector, dedicated to the development and commercialization of impactful gene therapies. Their flagship product, LUXTURNA, exemplifies their innovative approach to treatment, while their additional products and services demonstrate a holistic commitment to patient care, education, and research in genetic diseases.